First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial
1. 系统已在2025-12-08 11:21:01对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/j.ejca.2025.115807
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S0959804925005933
其他信息:
出版社: Elsevier BV
作者: Maeve A. Lowery; Lucjan S. Wyrwicz; Do-Youn Oh; Kai-Keen Shiu; Patricio Yañez; Yuxian Bai; Min-Hee Ryu; Jeeyun Lee; Fernando Rivera; Gustavo Vasconcelos Alves; Marcelo Garrido; Manuel González Fernández; Jin Li; Timuçin Çil; Felipe Melo Cruz; Shukui Qin; Yanfen Guan; Adriana Valderrama; Sonal Bordia; Sun Young Rha

